Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

By afschroeder • July 4, 2026

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin M, Sauder M, Gerdes S, Reyes-Servin O, Edem BE, Campbell J, Cresswell K, Kephart L, Li S, Yang YW, Bissonnette R. Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials. Br J Dermatol. 2026 Jul 3:ljag264. doi: 10.1093/bjd/ljag264. Epub ahead of print. PMID: 42397072.

Tags: Dermatology, Publications

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST

Coates LC, Gladman DD, Merola JF, Mrowietz U, Armstrong A, Baraliakos X, Tillett W, Kishimoto M, Reddy J, Teng L, Amouzadeh H, Deignan C, Mease[...]

GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic Arthritis/Psoriasis Care and Resource Limitations

Ma EJ, Boit R, Leung YY, Singla S, Fernández-Ávila D, Kalyoncu U, Armstrong AW. GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic[...]

Paradoxical melanoma in situ arising in a depigmented patch secondary to immunotherapy

Shah KS, Kang Y, Opene C. Paradoxical melanoma in situ arising in a depigmented patch secondary to immunotherapy. JAAD Case Rep. 2026 May 15;74:115-117. doi:[...]